Pathstone Family Office’s Ascendis Pharma A/S ASND Stock Holding History

Pathstone Family Office’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,484	Closed	-$523K	–	1223
2022 Q4	$523K	Sell	4,484 -44	-1%	-$5.11K	﹤0.01%	1075
2022 Q3	$468K	Buy	+4,528	New	+$429K	﹤0.01%	1100
2021 Q1	–	Sell	-70	Closed	-$12K	–	705
2020 Q4	$12K	Hold	70	–	–	﹤0.01%	839
2020 Q3	$11K	Buy	+70	New	+$10.1K	﹤0.01%	584

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pathstone Family Office's ASND Position: Q1 2023 in Review

Pathstone Family Office sold out of Ascendis Pharma A/S (ASND) in Q1 2023, closing a stake of 4,484 shares — an estimated $523K sold.

Pathstone Family Office first reported a position in ASND in Q3 2020 and held it in 4 quarters. The position peaked at $523K in Q4 2022. 164 funds tracked by Wall St. Rank hold ASND as of Q1 2023.

Pathstone Family Office reported no remaining Ascendis Pharma A/S position as of Q1 2023 after selling out during the quarter.
Pathstone Family Office sold 4,484 Ascendis Pharma A/S shares in Q1 2023, an estimated $523K.
Pathstone Family Office first reported a position in Ascendis Pharma A/S in Q3 2020 and held it in 4 quarters.
Pathstone Family Office's Ascendis Pharma A/S position peaked at $523K in Q4 2022.
164 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2023.

Based on Pathstone Family Office's 13F filing for Q1 2023, filed 15 May 2023.